Drug news
Januvia approved in UK for use in renally impaired diabetic patients
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Januvia (sitagliptin) from Merck Inc., in the UK for use in patients suffering from moderate to severe renal impairment. As a result, another treatment will be available for individuals with sub-optimum kidney function, who represent up to one third of all those with diabetes.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.